Target-specific CRISPR mutant
The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
1. An artificially engineered SpCas9 ( Streptococcus pyogenes Cas9) variant comprising:
an amino acid sequence having a mutated sequence of SEQ ID NO: 30 wherein SEQ ID NO: 30 has substitutions of F539S, M763I and K890N,
wherein the mutated sequence consists of mutation selected from the group consisting of:
i) mutation at site 112th position, 492th position, 671th position and 735th position in SEQ ID NO: 30, wherein the mutations are that,
lysine at 112th position (K112) is substituted with asparagine,
isoleucine at 492th position (1492) is substituted with phenylalanine,
arginine at 671th position (R671) is substituted with histidine, and
lysine at 735th position (K735) is substituted with threonine;
ii) mutation at site 350th position, 1007th position, and 1021th position in SEQ ID NO: 30, wherein the mutations are that,
isoleucine at 350th position (1350) is substituted with valine,
glutamic acid at 1007th position (E1007) is substituted with valine, and
methionine at 1021th position (M1021) is substituted with cysteine;
iii) mutation at site 1277th position in SEQ ID NO: 30, wherein the mutation is that,
serine at 1277th position (S1277) is substituted with glycine;
iv) mutation at site 1007th position, 1192th position in SEQ ID NO: 30, wherein the mutations are that,
glutamic acid at 1007th position (E1007) is substituted with glycine, and
lysine at 1192th position (K1192) is substituted with arginine;
v) mutation at site 889th position in SEQ ID NO: 30, wherein the mutation is that, alanine at 889th position (A889) is substituted with valine;
vi) mutation at site 1191th position in SEQ ID NO: 30, wherein the mutation is that, lysine at 1191th position (K1191) is substituted with glutamic acid; and
vii) mutation at site 1007th position in SEQ ID NO: 30, wherein the mutation is that,
glutamic acid at 1007th position (E1007) is substituted with one amino acid selected from alanine, asparagine, aspartic acid, glutamine, glycine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
2. The artificially engineered SpCas9 variant of claim 1 , wherein the artificially engineered SpCas9 variant comprising an amino acid sequence having a mutated sequence of SEQ ID NO: 30;
wherein the mutated sequence consists of a mutation at site 1007th position in SEQ ID NO: 30, wherein the mutation is that glutamic acid at 1007th position (E1007) is substituted with one amino acid selected from valine, glycine, alanine, leucine, proline, serine, and tyrosine.
3. The artificially engineered SpCas9 variant of claim 1 , wherein the artificially engineered SpCas9 variant comprising an amino acid sequence having a mutated sequence of SEQ ID NO: 30;
wherein the mutated sequence consists of mutation at site 1007th position in SEQ ID NO: 30, wherein the mutation is that glutamic acid at 1007th position (E1007) is substituted with leucine, or proline.
4. The artificially engineered SpCas9 variant of claim 1 , wherein the artificially engineered SpCas9 variant comprises a NLS (nuclear localization sequence or signal).
5. The artificially engineered SpCas9 variant of claim 4 , wherein the artificially engineered SpCas9 variant further comprises one or more functional domains selected from the group consisting of:
a tag for isolation and purification;
a deaminase; and
a domain selected from the group consisting of domains having methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity.
6. A composition for gene modification in a cell, comprising:
the artificially engineered SpCas9 variant of claim 1 or a nucleic acid encoding the artificially engineered SpCas9 variant of claim 1 ; and
a guide RNA or a nucleic acid encoding the guide RNA,
wherein the guide RNA is capable of targeting a gene and complexing with the artificially engineered SpCas9 variant.
7. The composition of claim 6 , wherein the artificially engineered SpCas9 variant comprises a NLS (nuclear localization sequence or signal).
8. The composition of claim 6 , wherein the guide RNA and the artificially engineered SpCas9 variant form a complex of ribonucleoprotein (RNP).
9. The composition of claim 6 , wherein the nucleic acid encoding the artificially engineered SpCas9 variant and the nucleic acid encoding the guide RNA are included in one or more vectors.
10. An artificially engineered SpCas9 variant comprising amino acid sequence SEQ ID NO: 31 or SEQ ID NO: 32.
11. A composition for gene modification in a cell, comprising:
an artificially engineered SpCas9 variant comprising amino acid sequence SEQ ID NO: 31 or SEQ ID NO: 32; and
a guide RNA or a nucleic acid encoding the guide RNA,
wherein the guide RNA is capable of targeting a gene and complexing with the artificially engineered SpCas9 variant.